Biaryl compositions and methods for modulating a kinase cascade
The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention relates to compounds of the formula I: or a pharmaceutically acceptable salt thereof. The compounds of the invention are useful for methods of protecting against or treating hearing loss, osteoporosis, cell proliferative disorders, obesity, diabetes, eye disease, stroke, atherosclerosis, neuropathic pain or hepatitis B.
1. A compound according to Formula IA
or a pharmaceutically acceptable salt thereof,
wherein: T is a bond;
X y is CY, N, or N—O;
X z is CZ;
Y is selected from hydrogen, hydroxyl, halogen, lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, and O-benzyl;
X a is CR a or N, or N—O;
X b is CR b ;
X c is CR c ;
X d is CR d ;
X e is CR e , N, or N—O;
R a , R b , R c , R d , R e , R 4 , R 5 , and R 6 are, independently, hydrogen, hydroxyl, halogen, P, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, O-benzyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-OH, COOH, COO-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl, SO 2 H, SO 2 -lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl,
wherein W is H, or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-aryl;
P is SO 3 H, OSO 3 H, OPO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NHR 20 R 21 ,
tetrazole, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-K, O—C(O)-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-L, NH-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-M, or O-aryl-Q, further wherein lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl is linear or branched alkyl;
K is C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 2 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
L is aryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 2 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
M is aryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 2 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
Q is aryl, OH, C(O)NH 2 , COOH, SO 3 H, OSO 3 H, PO 3 H 2 , OPO 3 H 2 , NH 2 , NHR 19 , NR 19 R 20 , SO 2 R 21 , glycoside, lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, or
R 19 , R 20 and R 21 are independently C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl or R 19 and R 20 taken together with the attached nitrogen atom form a five membered ring;
V is a bond, —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —O—CH 2 —, —OCH 2 CH 2 — or —OCH 2 CH 2 CH 2 —;
Z is (CHR 1 ) n —C(O)—NR 2 (CHR 3 ) m —Ar, where Ar is a substituted or unsubstituted aryl or nitrogen-containing heteroaryl group, R 1 , R 2 , and R 3 are independently H or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl; and
n is 1, or 2;
and m is 0, 1, or 2;
provided that at least one of R a , R b , R c , R d , R e , R 4 , R 5 , and R 6 is P and wherein only one of X a , X e , and X y is N or N—O.
2. The compound of claim 1 , wherein X y is N.
3. The compound of claim 1 , wherein Z is
and R 7 , R 8 , R 9 , R 10 , and R 11 are selected from hydrogen, hydroxyl, halogen, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-aryl, O-benzyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-OH, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-O—C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl,
where W is H, or C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl-aryl.
4. The compound of claim 3 , wherein at least one of R 7 , R 8 , R 9 , R 10 , and R 11 is halogen, C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkoxy, or O-benzyl.
5. The compound of claim 3 , wherein m is 1.
6. The compound of claim 1 , wherein R 4 and R 6 are each H.
7. The compound of claim 1 , wherein the compound is selected from
8. The compound of claim 2 , wherein X a , X c , X d , and X e are each C—H.
9. The compound of claim 3 , wherein n is 1.
10. The compound of claim 3 , wherein R 2 is H.
11. The compound of claim 3 , wherein R 1 and R 3 are each H.
12. The compound of claim 1 , wherein R 5 is halogen.
13. The compound of claim 12 , wherein R 5 is fluorine.
14. The compound of claim 1 , wherein P is O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-K.
15. The compound of claim 3 , wherein P is O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) alkyl-K, X y is N and X a , X c , X d , and X e are each C—H.
16. The compound of claim 14 , wherein P is O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) linear alkyl-K.
17. The compound of claim 14 , wherein P is O-lower (C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 ) branched alkyl-K.
18. The compound of claim 14 , wherein P is O-lower (C 2 or C 3 ) alkyl-K.
19. The compound of claim 14 , wherein K is selected from lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, COOH, and tetrazole.
20. The compound of claim 15 , wherein K is selected from lower C 1 , C 2 , C 3 , C 4 , C 5 , C 6 alkoxy, COOH, and tetrazole.
21. The compound of claim 20 , wherein n and m are each 1; R 1 , R 2 , R 3 are each H; R 8 is halogen, and R 7 , R 9 , R 10 and R 11 are hydrogen.
22. The compound of claim 21 , wherein R 5 is halogen and R 6 is hydrogen.
23. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
24. A pharmaceutical composition comprising a compound selected from
or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.